Here, we find that therapeutic inactivation of MAPK can result in Wnt and LGR5‐ISC signature reactivation in CRC, confirming two previous studies (Zhan et al, 2019; Lupo et al, 2020). This evidence concerns the gene LGR5 and colorectal carcinoma.